By reviewing the literature, we learned that inhibiting IGF2BP3 in breast cancer cells can enhance anti-tumor immunity through PD-L1-mediated T cell activation, exhaustion, and infiltration 39. Here, IGF2BP3 is linked to breast carcinoma.